Filtros de búsqueda

Lista de obras de Thomas Valerius

A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor Cells.

artículo científico publicado en 2015

Activated neutrophils as effector cells for bispecific antibodies ⬇️

artículo científico publicado el 1 de noviembre de 1997

An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement In Vivo.

artículo científico publicado en 2015

Antibody-dependent cellular cytotoxicity in patients on chronic hemodialysis.

artículo científico publicado en 2013

Clinical evaluation of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (Filgrastim) for treatment of advanced breast cancer ⬇️

artículo científico publicado el 1 de noviembre de 1997

Complement in antibody-based tumor therapy.

artículo científico publicado en 2014

Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET

artículo científico publicado en 2021

Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2m(1) antibody.

artículo científico publicado en 2013

Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.

artículo científico

Epidermal growth factor receptor targeting IgG3 triggers complement-mediated lysis of decay-accelerating factor expressing tumor cells through the alternative pathway amplification loop.

artículo científico publicado en 2014

Fc engineering of antibodies and antibody derivatives by primary sequence alteration and their functional characterization.

artículo científico publicado en 2014

HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity

artículo científico publicado en 2015

HLA Class II Antibodies Recruit G-CSF Activated Neutrophils for Treatment of B Cell Malignancies ⬇️

artículo científico publicado el 1 de julio de 1997

IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition

artículo científico publicado en 2019

Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting

artículo científico publicado en 2015

Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity.

artículo científico publicado en 2013

Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells.

artículo científico publicado en 2017

Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies

scientific article published on 01 March 2019

Renal Dysfunction in a Human Immunodeficiency Virus–Infected Patient Who Was Treated with Indinavir ⬇️

artículo científico publicado el 1 de noviembre de 1997

Response to Comment on "Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells".

artículo científico publicado en 2018

Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing

artículo científico publicado en 2015

Targeting FcαRI on Polymorphonuclear Cells Induces Tumor Cell Killing through Autophagy ⬇️

artículo científico publicado el 8 de junio de 2011

The novel multispecies Fc-specific Pseudomonas exotoxin A fusion protein α-Fc-ETA' enables screening of antibodies for immunotoxin development.

artículo científico publicado en 2015

Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells.

artículo científico publicado en 2016

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda